ArticleCell2024
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Abstract readPublished Erratum
In one paragraph
Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Assessing current capabilities for incorporating lipidomics in multiomics data integration.Briefings in bioinformatics · 2026Review
- Multi-omic characterization of nasopharyngeal carcinoma delineates the subtype-specific landscape of response to induction chemotherapy.Nature cancer · 2026Article
- Anatomical precision in the omics era: a proposed framework for selective para-aortic lymphadenectomy in epithelial ovarian cancer.Frontiers in medicine · 2026Review
- Emerging insights into alternative end‑joining: Mechanisms, genome instability and therapeutic opportunities in cancer (Review).International journal of oncology · 2025Review
- Comprehensive bioinformatics analysis of co-mutation ofTranslational cancer research · 2025Article
- The 2024 Report on the Human Proteome from the HUPO Human Proteome Project.Journal of proteome research · 2024Review
- NImmunity, inflammation and disease · 2024Review
- Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications.Nature reviews. Cancer · 2024Article
- Neutrophil surface RNAs promote entry to inflamed sites.Nature reviews. Immunology · 2024Article
Corrections and comments
- Erratum for
Authors and funding
47 authors.
Shrabanti Chowdhury
Jacob J Kennedy
Richard G Ivey
Oscar D Murillo
Noshad Hosseini
Xiaoyu Song
Francesca Petralia
Anna Calinawan
Sara R Savage
Anna B Berry
Boris Reva
Umut Ozbek
Azra Krek
Weiping Ma
Felipe da Veiga Leprevost
Jiayi Ji
Seungyeul Yoo
Chenwei Lin
Uliana J Voytovich
Yajue Huang
Sun-Hee Lee
Lindsay Bergan
Travis D Lorentzen
Mehdi Mesri
Henry Rodriguez
Andrew N Hoofnagle
Zachary T Herbert
Alexey I Nesvizhskii
Bing Zhang
Jeffrey R Whiteaker
David Fenyo
Wilson McKerrow
Joshua Wang
Stephan C Schürer
Vasileios Stathias
X Steven Chen
Mary Helen Barcellos-Hoff
Timothy K Starr
Boris J Winterhoff
Andrew C Nelson
Samuel C Mok
Scott H Kaufmann
Charles Drescher
Marcin Cieslik
Pei Wang
Michael J Birrer
Amanda G Paulovich
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MTumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI George S. Grills · 2019 to 2026
$24.1MProteogenomic Studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefitU01CA214114 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BIRRER, MICHAEL, PAULOVICH, AMANDA G · 2017 to 2021
$8.4MProteogenomic translator for cancer biomarker discovery towards precision medicineU24CA271114 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Avi Ma'ayan, Pei Wang · 2022 to 2026
$5.0MiPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTACU24CA210954 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, BING · 2016 to 2020
$4.9MSystems Biology based Proteogenomic Translator for Cancer Marker Discovery towards Precision MedicineU24CA210993 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHADT, ERIC E, WANG, PEI · 2016 to 2020
$4.6MMichigan Center for Translational Cancer Proteogenomics-Diversity SupplementU24CA271037 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Saravana Mohan Dhanasekaran, Alexey I Nesvizhskii · 2022 to 2026
$4.4MUniversity of Michigan Proteogenomics Data Analysis CenterU24CA210967 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, DHANASEKARAN, SARAVANA M · 2016 to 2020
$4.1MProteogenomic Data Analysis for Cancer Systems Biology and Clinical TranslationU24CA210972 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DING, LI, FENYO, DAVID · 2016 to 2020
$3.3MA proteomics research specialist in developing targeted mass spectrometry methods for quantifying proteins important in cancerR50CA211499 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Jeff Whiteaker · 2016 to 2026
$2.8MNCI NIH HHS P30 CA015083NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA240139NCI NIH HHS P50 CA136393NCI NIH HHS R50 CA211499NCI NIH HHS U01 CA214114NCI NIH HHS U24 CA210954NCI NIH HHS U24 CA210967NCI NIH HHS U24 CA210972NCI NIH HHS U24 CA210993NCI NIH HHS U24 CA271037NCI NIH HHS U24 CA271114NIH HHS S10 OD028685
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.